Virtual Reality-Supported Autism Education for Nursing Students (VR-AUTISM-NURS)

November 12, 2026 updated by: Edanur Tar Bolacali, Kirsehir Ahi Evran Universitesi

Effect of a Virtual Reality-Supported Autism Education Program for Nursing Students on Autism-Related Knowledge, Awareness, and Attitudes: A Randomized Controlled Trial

The goal of this clinical trial is to learn if a virtual reality (VR)-supported autism education program improves knowledge, awareness, and attitudes about autism spectrum disorder (ASD) in fourth-year nursing students. The main questions it aims to answer are:

  • Does the program increase nursing students' knowledge of autism?
  • Does the program increase their awareness of autism and improve their attitudes toward people with autism?

Researchers will compare students who take the program with students who receive no education during the study, to see if the program improves knowledge, awareness, and attitudes, and whether these effects last one month after the program.

Participants will:

  • Attend one 90-minute face-to-face session per week for 8 weeks (education group only). Sessions in weeks 1 to 7 use active learning methods such as group work and brainstorming. In week 8, each student watches a short (about 5-minute) 360-degree VR scenario that shows a hospital visit from the point of view of a child with autism, followed by a guided group discussion.
  • Complete questionnaires on autism knowledge, awareness, and attitudes before the program, after the program (week 8), and one month later.

Students in the control group will be offered the same program after the study ends.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background: Nurses working in primary care and child health services are in a key position to recognize early signs of autism spectrum disorder (ASD) and to refer children for timely assessment. However, nursing students often report limited knowledge and low confidence in this area. Immersive virtual reality (VR) allows learners to experience sensory and social situations from the perspective of a child with autism without involving children in the teaching process.

Design: This is a single-center, two-arm, parallel-group, open-label randomized controlled trial with pretest, posttest, and one-month follow-up measurements. The study will be reported according to CONSORT and the CONSORT-Outcomes 2025 extension.

Randomization: After baseline measurement, participants will be allocated 1:1 by simple randomization using a computer-generated sequence (randomizer.org). Randomization will be performed by an independent researcher not involved in delivering the intervention, and the allocation list will be concealed from the research team until assignment is complete. Data will be coded by group (Group A/Group B) and analyzed by a statistician blinded to group allocation.

Intervention content: Weekly modules cover the diagnostic framework of ASD, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes. Teaching methods include station rotation, six thinking hats, brainstorming, the six-shoe technique, and cooperative learning (inner-outer circle). Week 8 is a simulation session ("A Journey into the World of a Child with Autism") in which students experience an 8-year-old child's hospital visit first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing. Content will be reviewed by autism experts and piloted with nursing students before the trial.

Statistical analysis: Group-by-time effects across the three measurements will be analyzed with two-way repeated-measures ANOVA, or the nonparametric F1-LD-F1 model if assumptions are not met. Analyses will follow the intention-to-treat principle, and missing data will be handled by multiple imputation. Effect sizes (Cohen's d, partial eta squared) will be reported. The significance level is p<0.05.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Fourth-year student in the Department of Nursing, Faculty of Health Sciences, Kirsehir Ahi Evran University
  • Has completed the pediatric (child health and diseases) nursing course
  • Has not previously attended a structured education program on autism spectrum disorder
  • Agrees to participate voluntarily and signs the informed consent form
  • Is able to attend the education sessions and measurements

Exclusion Criteria:

  • Known health condition that may prevent the use of virtual reality (e.g., severe motion sickness or vertigo, epilepsy)
  • Not completing the baseline (pretest) measurements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: VR-Supported Autism Education

Participants will attend an 8-week modular autism education program with one 90-minute face-to-face session per week. Weeks 1-7 consist of active learning modules on autism spectrum disorder. Week 8 consists of a virtual reality simulation session followed by a structured debriefing.

An 8-week program with one 90-minute face-to-face session per week. Weeks 1-7 cover the diagnostic framework of autism spectrum disorder, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes, using station rotation, six thinking hats, brainstorming, six-shoe technique, and cooperative learning methods. In week 8, each student experiences an approximately 5-minute immersive 360-degree VR scenario of an 8-year-old child's hospital visit from the child's perspective, first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing.

No Intervention: Control

Participants will receive no education during the study period and will complete the same questionnaires at the same time points (baseline, week 8, and week 12). They will be offered the same education program after the follow-up measurement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Autism Knowledge Score (Knowledge about Childhood Autism among Health Workers Questionnaire)
Time Frame: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism knowledge will be measured with the Turkish version of the Knowledge about Childhood Autism among Health Workers (KCAHW) Questionnaire. It has 19 items covering social interaction, communication, behavioral patterns, and features of the disorder. Each correct answer scores 1 and each incorrect or "don't know" answer scores 0, giving a total score of 0 to 19. Higher scores indicate greater knowledge of childhood autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Autism Awareness Score (Autism Awareness Scale)
Time Frame: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism awareness will be measured with the Autism Awareness Scale, which has 32 items in 7 subscales (restricted interests and repetitive behaviors, social interaction and communication, causes of autism, peer relationships, key elements of intervention, physical characteristics, and early warning signs). Items are rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), with reverse-scored items, giving a total score of 32 to 160. Higher scores indicate greater awareness of autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)
Attitudes Toward Autism Score (Societal Attitudes Towards Autism Scale)
Time Frame: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Attitudes toward autism will be measured with the Turkish version of the Societal Attitudes Towards Autism (SATA) Scale, which has 26 items in 3 subscales (personal distance, knowledge, and social life). Items are rated on a 4-point scale, with reverse-scored items, giving a total score of 26 to 104. Higher scores indicate more positive attitudes toward individuals with autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 17, 2026

Primary Completion (Estimated)

January 15, 2027

Study Completion (Estimated)

February 28, 2027

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SYO.A3.26.005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared publicly because participants were informed in the consent process that their data would be used only by the research team for scientific purposes. Aggregate results will be published in a peer-reviewed journal. De-identified data may be made available by the principal investigator upon reasonable request after publication, subject to ethics committee approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.